Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel Angel Molina

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Expert Review of Respiratory Medicine|May 22, 2015
The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancerNiki Karachaliou, Miguel Angel Molina-Vila, Rafael Rosell
Translational Lung Cancer Research|March 26, 2015
Predicting resistance by selection of signaling pathwaysNiki Karachaliou, Rafael Rosell, Miguel Angel Molina, et al.
NPJ Precision Oncology|April 14, 2021
Panels and models for accurate prediction of tumor mutation burden in tumor samplesElizabeth Martínez-Pérez, Miguel Angel Molina-Vila, Cristina Marino-Buslje
Future Oncology (London, England)|April 21, 2009
IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumorsRafael Rosell, Jordi Bertran-Alamillo, Miguel Angel Molina, et al.
Translational Lung Cancer Research|March 26, 2015
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitorsJosé Miguel Sánchez-Torres, Santiago Viteri, Miguel Angel Molina, et al.
Current Opinion in Oncology|December 2, 2009
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancerRafael Rosell, Santiago Viteri, Miguel Angel Molina, et al.
Journal of Thoracic Disease|November 30, 2017
Possible application of circulating free tumor DNA in non-small cell lung cancer patientsNiki Karachaliou, Aaron E Sosa, Miguel Angel Molina, et al.
Current Pharmaceutical Design|October 22, 2013
Signaling pathways modulating dependence of lung cancer on mutant epidermal growth factor receptor and mechanisms of intrinsic and acquired resistance to tyrosine kinase inhibitorsLuciano Wannesson, Santiago Viteri, Carlota Costa, et al.
Human Mutation|January 11, 2019
Comutation and exclusion analysis in human tumors: A tool for cancer biology studies and for rational selection of multitargeted therapeutic approachesSoledad Ochoa, Elizabeth Martínez-Pérez, Diego Javier Zea, et al.
Revista Medica Del Instituto Mexicano Del Seguro Social|January 26, 2018
[Airway metaplasia related to smoking and environmental pollution through sputum]Floribel Ferman-Cano, Fernando Padilla-Santamaría, Luis Moreno-Venegas, et al.
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Expert Review of Respiratory Medicine|May 22, 2015
The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancerNiki Karachaliou, Miguel Angel Molina-Vila, Rafael Rosell
Translational Lung Cancer Research|March 26, 2015
Predicting resistance by selection of signaling pathwaysNiki Karachaliou, Rafael Rosell, Miguel Angel Molina, et al.
NPJ Precision Oncology|April 14, 2021
Panels and models for accurate prediction of tumor mutation burden in tumor samplesElizabeth Martínez-Pérez, Miguel Angel Molina-Vila, Cristina Marino-Buslje
Future Oncology (London, England)|April 21, 2009
IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumorsRafael Rosell, Jordi Bertran-Alamillo, Miguel Angel Molina, et al.
Translational Lung Cancer Research|March 26, 2015
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitorsJosé Miguel Sánchez-Torres, Santiago Viteri, Miguel Angel Molina, et al.
Current Opinion in Oncology|December 2, 2009
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancerRafael Rosell, Santiago Viteri, Miguel Angel Molina, et al.
Journal of Thoracic Disease|November 30, 2017
Possible application of circulating free tumor DNA in non-small cell lung cancer patientsNiki Karachaliou, Aaron E Sosa, Miguel Angel Molina, et al.
Current Pharmaceutical Design|October 22, 2013
Signaling pathways modulating dependence of lung cancer on mutant epidermal growth factor receptor and mechanisms of intrinsic and acquired resistance to tyrosine kinase inhibitorsLuciano Wannesson, Santiago Viteri, Carlota Costa, et al.
Human Mutation|January 11, 2019
Comutation and exclusion analysis in human tumors: A tool for cancer biology studies and for rational selection of multitargeted therapeutic approachesSoledad Ochoa, Elizabeth Martínez-Pérez, Diego Javier Zea, et al.
Revista Medica Del Instituto Mexicano Del Seguro Social|January 26, 2018
[Airway metaplasia related to smoking and environmental pollution through sputum]Floribel Ferman-Cano, Fernando Padilla-Santamaría, Luis Moreno-Venegas, et al.
Pageof 8